Brief Communication abstract
Nature Chemical Biology 4, 110 - 112 (2007)
Published online: 23 December 2007 | Corrected online: 3 January 2008 | doi:10.1038/nchembio.2007.58
Site selectivity of platinum anticancer therapeutics
Bin Wu1, Peter Dröge2 & Curt A Davey1
X-ray crystallographic and biochemical investigation of the reaction of cisplatin and oxaliplatin with nucleosome core particle and naked DNA reveals that histone octamer association can modulate DNA platination. Adduct formation also occurs at specific histone methionine residues, which could serve as a nuclear platinum reservoir influencing adduct transfer to DNA. Our findings suggest that the nucleosome center may provide a favorable target for the design of improved platinum anticancer drugs.
- Division of Structural and Computational Biology, School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551, Singapore.
- Division of Genomics and Genetics, School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551, Singapore.
Correspondence to: Curt A Davey1 e-mail: davey@ntu.edu.sg
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Certain Animal PoisonsNature Letters to Editor (09 Oct 1879)
A novel DNA structure induced by the anticancer bisplatinum compound crosslinked to a GpC site in DNANature Structural Biology Article (01 Jul 1995)
Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatinNature Letters to Editor (19 Oct 1995)
See all 6 matches for Research
